Author Index to Volume 52

Akechi T. See Uchitomi Y
Alam D. See Janicak PG
Alexopoulos GS. See Krishan KRR
Alexopoulos GS, Borson S, Cuthbert BN, Devanand DP, Mulsant BH, Olin JT, Oslin DW. Assessment of late life depression, 164
Alexopoulos GS, Buckwalter K, Olin J, Martinez R, Wainscott C, Krishan KRR. Cormorbidity on late life depression: an opportunity for research on mechanisms and treatment, 543
Alloy LB. See Davidson RJ
Altshuler LL. See McElroy SL; Suri R
Amaral DG. See Davidson RJ
Amo C. See Fernádez A
Amodio S. See Cavallaro R
Anderson GM. See Köhnke MD
Anderson TS. See Geraci M
Andreasen NC. See Chemerinski E; Corson PW
Araj H. See Matsushita S; Merikangas KR
Archibald SL. See Fennema-Notestine C
Arciniegas DB. See Rojas DC
Areán PA, Cook BL. Psychotherapy and combined psychotherapy/ pharmacotherapy for late life depression, 293
Aschauer HN. See Bailer U
Au TH. See Steingard RJ
Autio KA. See McElroy SL
Avila MT. See Sherr JD

Babich KS. See Charney DS
Bailer U, Leisch F, Meszaros K, Lenzinger E, Willinger U, Strobl R, Heiden A, Gebhardt C, Döge E, Fuchs K, Sieghart W, Kasper S, Hornik K, Aschauer HN. Genome scan for susceptibility loci for schizophrenia and bipolar disorder, 40
Baker GB. See Mejia JM
Barlow DH. See Hollon SD
Barnea-Goraly N. See Eliez S
Bauer LO. See Rangaswamy M
Bauer MS. See Wells KB
Baulieu E-E. See Belanoff JK
Bawn SD. See Rojas DC
Beardslee WR. See Hollon SD
Beasley CL, Zhang ZJ, Patten I, Reynolds GP. Selective deficits in prefrontal corticdal GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins, 708
Beedle D. See Janicak PG
Beers SR. See De Bellis MD
Begleiter H. See Rangaswamy M
Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu E-E, Schold C, Schatzberg AF. An open label trial of C-1073 (mifepristone) for psychotic major depression, 386
Bell CC. See Hollon SD
Bellodi L. See Cavallaro R
Benson BE. See Kimbrell TA
Bergman J. See Laakso A
Bernal G. See Hollon SD
Biederman J. See Costello EJ
Bilder RM. See Hoptman MJ
Bilder RM, Volavka J, Czobor P, Malhotra AK, Kennedy JL, Ni X, Goldman RS, Hoptman MJ, Sheitman B, Lindenmayer J-P, Citrome L, McEvoy JP, Kunz M, Chakos M, Cooper TB, Lieberman JA. Neurocognitive correlates of the COMT Val158Met polymorphism in chronic schizophrenia, 701
Birbaumer N. See Hermann C
Birnbaum R. See Pascual-Leone A
Blakely RD. See Tamminga CA
Blangero J. See Merikangas KR
Blaxton TA. See Sherr JD
Blehar M. See Frank E
Boas DA. See Strangman G
Boksa P. See Flores C
Boksman K. See Lanius RA
Borson S. See Alexopoulos GS
Boshuisen ML, Ter Horst GJ, Paans AMJ, Reinders AATS, den Boer JA. rCBF differences between panic disorder patients and control subjects during anticipatory anxiety and rest, 126
Bouton ME. Context, ambiguity, and unlearning: sources of relapse after behavioral extinction, 976
Bowley MP, Drevets WC, Öngür D, Price JL. Low glial numbers in the amygdala in major depressive disorder, 404
Brady L. See Tamminga CA
Brecher M. See Geller W
Bregartner TA. See George TP
Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P, Friedman JH. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease, 438
Brent L, Koban T, Ramirez S. Abnormal, abusive, and stress-related behaviors in baboon mothers, 1047
Brody S. High-dose ascorbic acid increases intercourse frequency and improves mood: a randomized controlled clinical trial, 371
Brooks WM. See Villarreal G
Bruce ML. See Wells KB
Bruce ML. Psychosocial risk factors for depressive disorders in late life, 175
Bucan M. See Nestler EJ
Buchkremer G. See Köhnke MD
Buckwalter K. See Alexopoulos GS; Krishan KRR
Burmeister M. See Merikangas KR
Bush G. See Davidson RJ

Caine ED. See Conwell Y
Carlson JP. See Rojas DC
Carney R. See Krishan KRR
Carter CS. See Tamminga CA
Cassidy F. See Belanoff JK
Cavallaro R, Galardi G, Cavallini MC, Henin M, Amodio S, Bellodi L, Comi G. Obsessive compulsive disorder among idiopathic focal dystonia patients: an epidemiological and family study, 356
Cavallini MC. See Cavallaro R
Chakos M. See Bilder RM
Chakravarti A. See Merikangas KR
Chang C-G. See Lyoo IK
Charlson M, Peterson JC. Medical comorbidity and late life

© 2002 Society of Biological Psychiatry

0006-3223/02/$22.00
PII S0006-3223(02)01889-9

depression: what is known and what are the unmet needs?, 226
Charney DS. See Gold PW; Pine DS; Reynolds CF III
Charney DS, Babich KS. Foundation for the NIMH strategic plan for mood disorders research, 455
Chemerinski E, Nopoulos PC, Crespo-Facorro B, Andreasen NC, Magnotta V. Morphology of the ventral frontal cortex in schizophrenia: relationship with social dysfunction, 1
Cho E. See Essex MJ
Chorlian DB. See Rangaswamy M
Cintron CB. See Steingard RJ
Citrome L. See Bilder RM
Clarke GN. See Hollon SD
Cohen JD. See Davidson RJ
Cohen PD. See Krishan KRR
Comi G. See Cavallaro R
Condren R. See Walsh M-T
Connor DF. See Steingard RJ
Constable RT. See Shaywitz BA
Conwell Y, Duberstein PR, Caine ED. Risk factors for suicide in later life, 193
Cook BL. See Areán PA
Cooper KL. See Mostofsky SH
Cooper TB. See Bilder RM
Copolov DL. See Yücel M
Corson PW, O'Leary DS, Miller DD, Andreasen NC. The effects of neuroleptic medications on basal ganglia blood flow in schizophreniform disorders: a comparison between the neuroleptic-naïve and medicated states, 855
Costello EJ, Pine DS, Hammen C, March JS, Plotsky PM, Weissman MM, Biederman J, Goldsmith HH, Kaufman J, Lewinsohn PM, Hellander M, Hoagwood K, Koretz DS, Nelson CA, Leckman JF. Development and natural history of mood disorders, 529
Courchesne E. See Pierce K
Crabbe JC Jr. See Merikangas KR
Crespo-Facorro B. See Chemerinski E
Crowe SF. See Yücel M
Cubells JF. See Köhnke MD
Cuthbert BN. See Alexopoulos GS
Czéh B, Welt T, Fischer AK, Erhardt A, Schmitt W, Müller MB, Toschi N, Fuchs E, Keck ME. Chronic psychosocial stress and concomitant repetitive transcranial magnetic stimulation: effects on stress hormone levels and adult hippocampal neurogenesis, 1057
Czobor P. See Bilder RM

d'Alfonso AAL. See van Honk J
Davidson RJ, Lewis DA, Alloy LB, Amaral DG, Bush G, Cohen JD, Drevets WC, Farah MJ, Kagan J, McClelland JL, Nolen-Hoeksema S, Peterson BS. Neural and behavioral substrates of mood and mood regulation, 478
Davis KL. See Tamminga CA
Davis M, Myers KM. The role of glutamate and gamma-aminobutyric acid in fear extinction: clinical implications for exposure therapy, 998
De Bellis MD, Keshavan MS, Shifflett H, Iyengar S, Beers SR, Hall J, Moritz G. Brain structures in pediatric maltreatment-related posttraumatic stress disorder: a sociodemographically matched study, 1066
de Haan EHF. See van Honk J
de Kloet ER. See Rinne T
DeBattista C. See Belanoff JK
DelBello MP. See López-Larson MP
Delong M. See Krishan KRR
den Boer JA. See Boshuisen ML
Denckla MB. See Mostofsky SH
Denicoff KD. See McElroy SL
Densmore M. See Lanius RA
Depaulo JR Jr. See Merikangas KR
DeRijk RH. See Rinne T
Dettling AC, Feldon J, Pryce CR. Repeated parental deprivation in the infant common marmoset (Callithrix Jacchus, primates) and analysis of its effects on early development, 1037
Devanand DP. See Alexopoulos GS
Devanand DP. Comorbid psychiatric disorders in late life depression, 236
Dew MA. See Krishan KRR
Dinan T. See Walsh M-T
Dingledine R. See Tamminga CA
Döge E. See Bailer U
Dowd SM. See Janicak PG
Drayer RA. See Schulz R
Drevets WC. See Bowley MP; Davidson RJ; Gold PW
Driscoll I. See Villarreal G
Duberstein PR. See Conwell Y
Duman RS. See Nestler EJ
Durham M. See Wells KB

Elbert T. See Fernádez A
Eliez S, Barnea-Goraly N, Schmitt JE, Liu Y, Reiss AL. Increased basal ganglia volumes in velo-cardio-facial syndrome (deletion 22q11.2), 68
Elliott A. See Sherr JD
Entsuah AR. See Stahl SM
Epel ES. See Stroud LR
Erhardt A. See Czéh B
Ervin FR. See Mejia JM
Escalona R. See Villarreal G
Escobar J. See Wells KB
Essex MJ, Klein MH, Cho E, Kalin NH. Maternal stress beginning in infancy may sensitize children to later stress exposure: effects overview on cortisol and behavior, 776
Essock S. See Frank E
Evans D. See Krishan KRR

Farah MJ. See Davidson RJ
Faraone SV. See Wilcox MA
Farchione TR, Moore GJ, Rosenberg DR. Proton magnetic resonance spectroscopic imaging in pediatric major depression, 86
Fatemi SH, Halt AR, Stary JM, Kanodia R, Schultz SC, Realmuto GR. Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices, 805
Feingold A. See George TP
Feldman PD. See Breier A
Feldon J. See Dettling AC; Leumann L
Fennema-Notestine C, Stein MB, Kennedy CM, Archibald SL, Jernigan TL. Brain morphometry in female victims of intimate partner violence with and without posttraumatic stress disorder, 1089
Ferchland I. See Breier A
Fernández A, Maestú F, Amo C, Gil P, Fehr T, Wienbruch C, Rockstroh B, Elbert T, Ortiz T. Focal temporoparietal slow activity in Alzheimer's disease revealed by magnetoencephalography, 764
Fink M. See Kellner CH
Fischer AK. See Czéh B
Fletcher JM. See Klorman R; Shaywitz BA

Flor H. See Hermann C
Flores C, Stewart J, Salmaso N, Zhang Y, Boksa P. Astrocytic basic fibroblast growth factor expression in dopaminergic regions after perinatal anoxia, 362
Foa ED, Franklin ME, Moser J. Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination?, 987
Ford D. See Wells KB
Foulks E. See Merikangas KR
Franciosi LP. See Hollon SD
Frank E, Rush AJ, Blehar M, Essock S, Hargreaves W, Hogan M, Jarrett R, Johnson RL, Katon WJ, Lavori P, McNulty JP, Niederehe G, Ryan N, Stuart G, Thomas SB, Tollefson GD, Vitiello B. Skating to where the puck is going to be: a plan for clinical trials and translation research in mood disorders, 631
Frank GK, Kaye WH, Meltzer CC, Price JC, Greer P, McConaha C, Skovira K. Reduced 5-HT2A receptor binding after recovery from anorexia nervosa, 896
Franke L, Uebelhack R, Müller-Oerlinghausen B. Low CSF 5-HIAA level in high-lethality suicide attempers: fact or artifact?, 375–corr
Franklin ME. See Foa ED
Fredrikson M. See Tillfors M
Freimer NB. See Merikangas KR
Friedman JH. See Breier A
Frye MA. See McElroy SL
Fuchs E. See Czéh B
Fuchs K. See Bailer U
Fulbright RK. See Shaywitz BA
Furmark T. See Tillfors M

Gaertner I. See Köhnke MD
Galardi G. See Cavallaro R
Gati JS. See Lanius RA
Gebhardt C. See Bailer U
Gehr T. See Fernádez A
Geller W, Smith M, Winter H, Brecher M. Comment on "Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin," 915–corr
Gelowitz DL, Rakic P, Goldman-Rakic PS, Selemon LD. Craniofacial dysmorphogenesis in fetally irradiated nonhuman primates: implications for the neurodevelopmental hypothesis of schizophrenia, 716
George MS. See Kimbrell TA
George TP, Vessicchio JC, Termine A, Bregartner TA, Feingold A, Rounsaville BJ, Kosten TR. A placebo controlled trial of bupropion for smoking cessation in schizophrenia, 53
Geraci M, Anderson TS, Slate-Cothren S, Post RM, McCann UD. Pentagastrin-induced sleep panic attacks: panic in the absence of elevated baseline arousal, 1183
Gershenfeld HK. See Nestler EJ
Gil P. See Fernádez A
Gispen-de Wied CC. See Oranje B
Glenthoj BY. See Mackeprang T
Goekoop JG. See Rinne T
Goff DC. See Pascual-Leone A
Gold PW, Drevets WC, Charney DS. New insights into the role of cortisol and the glucocorticoid receptor in severe depression, 381
Goldman RS. See Bilder RM
Goldman-Rakic PS. See Gelowitz DL
Goldsmith HH. See Costello EJ
Golier JA. See Yehuda R
Gonzalez J. See Wells KB
Gordon C. See Krishan KRR
Gordon E. See Loughland CM
Gore JC. See Shaywitz BA
Gorman JM. See Kent JM; Khan A; Tamminga CA
Gould E. See Nestler EJ
Greer P. See Frank GK
Griego JA. See Villarreal G
Grigoriadis DE. See Tamminga CA
Grillon C. Startle reactivity and anxiety disorders: aversive conditioning, context, and neurobiology, 958
Grossman R. See Yehuda R
Gupta M. See Lanius RA

Haaparanta M. See Laakso A
Hall J. See De Bellis MD
Halligan SL. See Yehuda R
Halt AR. See Fatemi SH
Hamilton DA. See Villarreal G
Hammen C. See Costello EJ
Han H. See Klimek V
Han MH. See Lyoo IK
Hargreaves W. See Frank E
Hart BL. See Villarreal G
Harvey PD. See Mitropoulou V
Hasegawa K. See Ono K
Hauger RL. See Morgan CA III
Hazlett G. See Morgan CA III
Heiden A. See Bailer U
Hellander M. See Costello EJ
Hen R. See Nestler EJ
Henderson DC. See Tamminga CA
Hendrick V. See Suri R
Henin M. See Cavallaro R
Hennen J. See Steingard RJ
Hermann C, Ziegler S, Birbaumer N, Flor H. Psychopsychological and subjective indicators of aversive Pavlovian conditioning in generalized social phobia, 328
Herscovitch P. See Kimbrell TA
Herva A. See Timonen M
Hietala J. See Laakso A
Higuchi S. See Matsushita S
Hillmann A. See Walsh M-T
Hoagwood K. See Costello EJ; Wells KB
Hogan M. See Frank E
Holahan JM. See Klorman R
Hollon SD, Muñoz RF, Barlow DH, Beardslee WR, Bell CC, Bernal G, Clarke GN, Franciosi LP, Kazdin AE, Kohn L, Linehan MM, Markowitz JC, Miklowitz DJ, Persons JB, Niederehe G, Sommers D. Psychosocial intervention development for the prevention and treatment of depression: promoting innovation and increasing access, 610
Holsboer F. See Modell S
Hoptman MJ. See Bilder RM
Hoptman MJ, Volavka J, Johnson G, Weiss E, Bilder RM, Lim KO. Frontal white matter microstructure, aggression, and impulsivity in men with schizophrenia: a preliminary study, 9
Hornik K. See Bailer U
Horwitz SM. See Wells KB
Hostetter A. See Suri R
Hoyt G. See Morgan CA III
Husain M. See Kellner CH

Inagaki M. See Uchitomi Y
Innes-Brown H. See Michie PT
Innis RB. See Tamminga CA
Ising M. See Modell S
Iwatsubo T. See Matsushita S
Iyengar S. See De Bellis MD

Jablensky AV. See Michie PT

Janicak PG, Viana M, Dowd SM, Martis B, Beedle D, Alam D, Krasuski J, Strong MJ, Sharma R, Rosen C. Comment on "Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: preliminary results of a randomized trial," 1032–corr (reply)
Jarrett R. See Frank E
Jayaraman A. See Yeragani VK
Jentsch JD, Olausson P, Nestler EJ, Taylor JR. Stimulation of protein kinase A activity in the rat amygdala enhances reward-related learning, 111
Jernigan TL. See Fennema-Notestine C
Johnson G. See Hoptman MJ
Johnson RL. See Frank E
Jokelainen J. See Timonen M
Jones KA. See Rangaswamy M
Jurjus G. See Miguel-Hidalgo JJ

Kadam DL. See Breier A
Kagan J. See Davidson RJ
Kagaya A. See Uchitomi Y
Kahn RS. See Oranje B
Kalin NH. See Essex MJ
Kanodia R. See Fatemi SH
Kasper S. See Bailer U
Kates WR. See Mostofsky SH
Katon WJ. See Frank E
Kaufman J. See Costello EJ
Kaufmann PG. See Krishan KRR
Kaufmann WE. See Mostofsky SH
Kaye WH. See Frank GK
Kazdin AE. See Hollon SD
Keck ME. See Czéh B
Keck PE Jr. See McElroy SL
Kellner CH, Husain M, Petrides G, Fink M, Rummans T. Comment on "Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: preliminary results of a randomized trial," 1032–corr
Kennedy CM. See Fennema-Notestine C; Stein MB
Kennedy JL. See Bilder RM; Ni X
Kenny D. See Walsh M-T
Kent JM, Mathew SJ, Gorman JM. Molecular targets in the treatment of anxiety, 1008
Keshavan MS. See De Bellis MD; Yao JK
Kessels RPC. See van Honk J
Ketter TA. See Kimbrell TA
Khan A, Khan SR, Leventhal RM, Krishnan RR, Gorman JM. An application of the revised CONSORT standards to FDA summary reports of recently approved antidepressants and antipsychotics, 62
Khan SR. See Khan A
Killen J. See Tamminga CA
Kimbrell TA, Ketter TA, George MS, Little JT, Benson BE, Willis MW, Herscovitch P, Post RM. Comment on "Regional cerebral glucose utilization in patients with a range of severities of unipolar depression," 1031–corr (reply)
Klein MH. See Essex MJ
Klimek V, Schenck JE, Han H, Stockmeier CA, Ordway GA. Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study, 740
Klorman R, Thatcher JE, Shaywitz SE, Fletcher JM, Marchione KE, Holahan JM, Stuebing KK, Shaywitz BA. Effects of event probability and sequence on children with attention-deficit/hyperactivity, reading, and math disorder, 795
Koban T. See Brent L
Kodituwakku PW. See Villarreal G
Koester S. See Nestler EJ
Kohn L. See Hollon SD
Köhnke AM. See Köhnke MD
Köhnke MD, Zabetian CP, Anderson GM, Kolb W, Gaertner I, Buchkremer G, Vonthein R, Schick S, Lutz U, Köhnke AM, Cubells JF. A genotype-controlled analysis of plasma dopamine b-hydroxylase in healthy and alcoholic subjects: evidence for alcohol-related differences in noradrenergic function, 1151
Kolb W. See Köhnke MD
Koretz DS. See Costello EJ; Merikangas KR
Kosten TR. See George TP
Kraemer H. See Krishan KRR
Krasuski J. See Janicak PG
Krishan KRR. See Alexopoulos GS
Krishan KRR, Delong M, Kraemer H, Carney R, Spiegel D, Gordon C, McDonald W, Dew MA, Alexopoulos G, Buckwalter K, Cohen PD, Evans D, Kaufmann PG, Olin J, Otey E, Wainscott C. Comorbidity of depression with other medical diseases in the elderly, 559
Krishnan KRR. Biological risk factors in late life depression, 185
Krishnan RR. See Khan A
Kristiansen KT. See Mackeprang T
Kugaya A. See Uchitomi Y
Kunz M. See Bilder RM
Kuperman S. See Rangaswamy M
Kupka RW. See McElroy SL
Kwon JS. See Lyoo IK

Laakso A, Vilkman H, Bergman J, Haaparanta M, Solin O, Syvälahti E, Salokangas RKR, Hietala J. Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects, 759
Lanius RA, Williamson PC, Boksman K, Densmore M, Gupta M, Neufeld RWJ, Gati JS, Menon RS. Brain activation during script-driven imagery induced dissociative responses in PTSD: a functional magnetic resonance imaging investigation, 305
Lauer CJ. See Modell S
Laughren TP. See Tamminga CA
Lavori P. See Frank E
Lawson W. See Wells KB
Leckman JF. See Costello EJ
Lederhendler I. See Nestler EJ
Lee L. See Ni X
Lee SI. See Lyoo IK
Lee SJ. See Lyoo IK
Leisch F. See Bailer U
Lenox M. See Steingard RJ
Lenzinger E. See Bailer U
Leumann L, Feldon J, Vollenweider FX, Ludewig K. Effects of typical and atypical antipsychotics on prepulse inhibition and latent inhibition in chronic schizophrenia, 729
Leventhal RM. See Khan A
Lewinsohn PM. See Costello EJ
Lewis DA. See Davidson RJ
Lewis L. See Wells KB
Lichtenstein W. See Merikangas KR
Lieberman JA. See Bilder RM
Lim KO. See Hoptman MJ
Lindenmayer J-P. See Bilder RM
Linehan MM. See Hollon SD
Little JT. See Kimbrell TA
Liu Y. See Eliez S

Loganovsky K. Comment on "Abnormalities of thalamic volume and shape detected in fetally irradiated rhesus monkeys with high dimensional brain mapping," 911–corr
López-Larson MP, DelBello MP, Zimmerman ME, Schwiers ML, Strakowski SM. Regional prefrontal gray and white matter abnormalities in bipolar disorder, 93
Loughland CM, Williams LM, Gordon E. Schizophrenia and affective disorder show different visual scanning behavior for faces: a trait versus state-based distinction?, 338
Ludewig K. See Leumann L
Lutz U. See Köhnke MD
Lyketsos CG, Olin J. Depression in Alzheimer's disease: overview and treatment, 243
Lyon GR. See Shaywitz BA
Lyoo IK, Kwon JS, Lee SJ, Han MH, Chang C-G, Seo CS, Lee SI, Renshaw PF. Decrease in genu of the corpus callosum in medication-naïve, early-onset dysthymia and depressive personality disorder, 1134

Macciardi FM. See Ni X
Mackeprang T, Kristiansen KT, Glenthoj BY. Effects of antipsychotics on prepulse inhibition of the startle response in drug-naïve schizophrenic patients, 863
Maestú F. See Fernádez A
Magnotta V. See Chemerinski E
Maldari LA. See Mitropoulou V
Malhotra AK. See Bilder RM
Manji HK. See Nestler EJ; Payne JL
Mann JJ, Placidi GPA. Low CSF 5-HIAA level in high-lethality suicide attempers: fact or artifact?, 375–corr (reply)
Manoach DS. See Pascual-Leone A
Marazziti D. A further support to the hypothesis of a link between serotonin, autism, and the cerebellum, 143–corr
March JS. See Costello EJ
Marchione KE. See Klorman R; Shaywitz BA
Markowitz JC. See Hollon SD
Marteinsdottir I. See Tillfors M
Martinez R. See Alexopoulos GS
Martis B. See Janicak PG
Maruff P. See Yücel M
Maruyama M. See Matsushita S
Mathew SJ. See Kent JM
Matsui T. See Matsushita S
Matsuoka Y. See Uchitomi Y
Matsushita S, Arai H, Okamura N, Ohmori T, Takasugi K, Matsui T, Maruyama M, Iwatsubo T, Higuchi S. Clinical and biomarker investigation of a patient with a novel presenilin-1 mutation (A431V) in the mild cognitive impairment stage of Alzheimer's disease, 907
McCann UD. See Geraci M
McClelland JL. See Davidson RJ
McConaha C. See Frank GK
McDonald W. See Krishan KRR
McDonald WM. See Tamminga CA
McElroy SL, Suppes T, Keck PE Jr, Denicoff KD, Nolen WA, Altshuler LL, Rush AJ, Kupka RW, Frye MA, Autio KA, Post RM. Early physical and sexual abuse associated with an adverse course of bipolar illness, 843–corr (reply)
McEvoy JP. See Bilder RM
McGuire T. See Wells KB
McNally RJ. Anxiety sensitivity and panic disorder, 938
McNulty JP. See Frank E
Meaney MJ. See Nestler EJ
Mejia JM, Ervin FR, Baker GB, Palmour RM. Monoamine oxidase inhibition during brain development induces pathological aggressive behavior in mice, 811
Meltzer CC. See Frank GK
Mencl E. See Shaywitz BA
Menon RS. See Lanius RA
Merikangas KR, Chakravarti A, Moldin SO, Araj H, Blangero J, Burmeister M, Crabbe JC Jr, Depaulo JR Jr, Foulks E, Freimer NB, Koretz DS, Lichtenstein W, Mignot E, Reiss AL, Risch NJ, Takahashi JS. Future of genetics of mood disorders research, 457
Meszaros K. See Bailer U
Michie PT, Innes-Brown H, Todd J, Jablensky AV. Duration mismatch negativity in biological relatives of patients with schizophrenia spectrum disorders, 749
Mignot E. See Merikangas KR
Miguel-Hidalgo JJ, Wei J, Overholser AJ, Jurjus G, Stockmeier CA, Rajkowska G. Glia pathology in the prefrontal cortex in alcohol dependence with and without depressive symptoms, 1121
Miklowitz DJ. See Hollon SD
Miller DD. See Corson PW
Mineka S, Öhman A. Phobias and preparedness: the selective, automatic, and encapsulated nature of fear, 927
Miranda J. See Wells KB
Mitropoulou V, Harvey PD, Maldari LA, Moriarty PJ, New AS, Silverman JM, Siever LJ. Neuropsychological performance in schizotypal personality disorder: evidence regarding diagnostic specificity, 1175
Modell S, Ising M, Holsboer F, Lauer CJ. The Munich vulnerability study on affective disorders: stability of polysomnographic findings over time, 430
Moldin SO. See Merikangas KR
Moore GJ. See Farchione TR
Morgan CA III, Rasmusson AM, Wang S, Hoyt G, Hauger RL, Hazlett G. Neuropeptide-Y, cortisol, and subjective distress in humans exposed to acute stress: replication and extension of previous report, 136
Moriarty PJ. See Mitropoulou V
Moritz G. See De Bellis MD
Moser J. See Foa ED
Mostofsky SH, Cooper KL, Kates WR, Denckla MB, Kaufmann WE. Smaller prefrontal and premotor volumes in boys with attention-deficit/hyperactivity disorder, 785
Müller MB. See Czéh B
Mulsant BH. See Alexopoulos GS; Whyte EM
Mundo E. See Ni X
Muñoz RF. See Hollon SD
Murphy GM Jr. See Tamminga CA
Myers C. See Sherr JD
Myers KM. See Davis M

Naiki H. See Ono K
Nakano T. See Uchitomi Y
Nelson CA. See Costello EJ
Nemeroff CB. See Tamminga CA
Nestler EJ. See Jentsch JD
Nestler EJ, Gould E, Manji H, Bucan M, Duman RS, Gershenfeld HK, Hen R, Koester S, Lederhendler I,

Meaney MJ, Robbins T, Winsky L, Zalcman S. Preclinical models: status of basic research in depression, 503
Neufeld RWJ. See Lanius RA
New AS. See Mitropoulou V
Ni X. See Bilder RM
Ni X, Trakalo JM, Mundo E, Macciardi FM, Parikh S, Lee L, Kennedy JL. Linkage disequilibrium between dopamine D1 receptor gene (DRD1) and bipolar disorder, 1144
Niederehe G. See Frank E; Hollon SD
Nolen WA. See McElroy SL
Nolen-Hoeksema S. See Davidson RJ
Nopoulos PC. See Chemerinski E

O'Connor SJ. See Rangaswamy M
Öhman A. See Mineka S
Ohmori T. See Matsushita S
Okamura N. See Matsushita S
Olausson P. See Jentsch JD
O'Leary DS. See Corson PW
Olin J. See Alexopoulos GS; Krishan KRR; Lyketsos CG
Olin JT. See Alexopoulos GS
Öngür D. See Bowley MP
Ono K, Hasegawa K, Yamada M, Naiki H. Nicotine breaks down preformed Alzheimer's b-amyloid fibrils in vitro, 880
Oranje B, Gispen-de Wied CC, Verbaten MN, Kahn RS. Modulating sensory gating in healthy volunteers: the effects of ketamine and haloperidol, 887
Ordway GA. See Klimek V
Ortiz T. See Fernádez A
Oslin DW. See Alexopoulos GS
Otey E. See Krishan KRR
Otto MW. Learning and "unlearning" fears: preparedness, neural pathways, and patients, 917–ed
Overholser AJ. See Miguel-Hidalgo JJ

Paans AMJ. See Boshuisen ML
Palmour RM. See Mejia JM
Pantelis C. See Yücel M
Parikh S. See Ni X
Pascual-Leone A, Manoach DS, Birnbaum R, Goff DC. Motor cortical excitability in schizophrenia, 24
Patten I. See Beasley CL
Paul SM. See Tamminga CA
Payne JL, Quiroz JA, Zarate CA Jr, Manji HK. Timing is everything: does the robust upregulation of noradrenergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation?, 921
Peltola O. See Timonen M
Persons JB. See Hollon SD
Pesce V. See Yeragani VK
Peterson BS. See Davidson RJ
Peterson JC. See Charlson M
Petrides G. See Kellner CH
Petropoulos H. See Villarreal G
Pettegrew JW. See Yao JK
Pierce K, Courchesne E. A further support to the hypothesis of a link between serotonin, autism, and the cerebellum, 143–corr (reply)
Pincus H. See Wells KB
Pine DS. See Costello EJ
Pine DS, Charney DS. Children, stress, and sensitization: an integration of basic and clinical research on emotion?, 773
Pizzagalli DA, Nitschke JB, Oakes TR, Hendrick AM, Horras KA, Larson CL, Abercrombie HC, Schaefer SM, Koger JV, Benca RM, Pascual-Marqui RD, Davidson RJ. Brain electrical tomography in depression: the importance of symptom severity, anxiety, and melancholic features, 73
Placidi GPA. See Mann JJ
Plotsky PM. See Costello EJ
Porjesz B. See Rangaswamy M
Post RM. See Geraci M; Kimbrell TA; McElroy SL
Price JC. See Frank GK
Price JL. See Bowley MP
Pryce CR. See Dettling AC
Pugh KR. See Shaywitz BA

Quiroz JA. See Payne JL

Rajkowska G. See Miguel-Hidalgo JJ
Rakic P. See Gelowitz DL
Ramirez S. See Brent L
Rangaswamy M, Porjesz B, Chorlian DB, Wang K, Jones KA, Bauer LO, Rohrbaugh J, O'Connor SJ, Kuperman S, Reich T, Begleiter H. Beta power in the EEG of alcoholics, 831
Rapee RM. The development and modification of temperamental risk for anxiety disorders: prevention of a lifetime of anxiety?, 947
Räsänen P. See Timonen M
Rasmusson AM. See Morgan CA III
Realmuto GR. See Fatemi SH
Reddy RD. See Yao JK
Reich T. See Rangaswamy M
Reinders AATS. See Boshuisen ML
Reiss AL. See Eliez S; Merikangas KR
Reite ML. See Rojas DC
Renshaw PF. See Lyoo IK; Steingard RJ
Reynolds CF III, Charney DS. Unmet needs in the diagnosis and treatment of mood disorders in later life, 145
Reynolds GP. See Beasley CL
Reynolds MM. Mood disorders in late life: a patient's perspective, 148
Rinne T, de Kloet ER, Wouters L, Goekoop JG, DeRijk RH, van den Brink W. Hyperresponsiveness of hypothalamic-pituitary-adrenal axis to combined dexamethasone/corticotropin-releasing hormone challenge in female borderline personality disorder subjects with a history of sustained childhood abuse, 1102
Risch NJ. See Merikangas KR
Robbins T. See Nestler EJ
Rockstroh B. See Fernádez A
Rohrbaugh J. See Rangaswamy M
Rojas DC, Bawn SD, Carlson JP, Arciniegas DB, Teale PD, Reite ML. Alterations in tonotopy and auditory cerebral asymmetry in schizophrenia, 32
Rollman BL. See Schulz R
Roose S. See Yeragani VK
Rosen C. See Janicak PG
Rosenberg DR. See Farchione TR
Rothman DL. See Shen J
Rothschild AJ. See Belanoff JK
Rounsaville BJ. See George TP
Rowland LM. See Villarreal G
Rudolph RL. See Stahl SM
Rudorfer MV. See Tamminga CA
Rummans T. See Kellner CH
Rush AJ. See Frank E; McElroy SL
Ryan M. See Walsh M-T
Ryan N. See Frank E

Salmaso N. See Flores C
Salokangas RKR. See Laakso A
Salovey P. See Stroud LR
Salzman C, Wong E, Wright BC. Drug and ECT treatment of depression in the elderly, 1996–2001: a literature review, 265

Sausville E. See Tamminga CA
Savage GR. See Yücel M
Schatzberg AF. See Belanoff JK; Tamminga CA
Scheffler R. See Wells KB
Schenck JE. See Klimek V
Schick S. See Köhnke MD
Schmitt JE. See Eliez S
Schmitt W. See Czéh B
Schold C. See Belanoff JK
Schultz SC. See Fatemi SH
Schulz R, Drayer RA, Rollman BL. Depression as a risk factor for non-suicide mortality in the elderly, 205
Schutter DJLG. See van Honk J
Schwenk TL. Diagnosis of late life depression: the view from primary care, 157
Schwiers ML. See López-Larson MP
Scolnick EM. See Tamminga CA
Scolnick EM. Discovery and development of antidepressants: a perspective from a pharmaceutical discovery company, 154–comm
Selemon LD. See Gelowitz DL
Seo CS. See Lyoo IK
Sharma R. See Janicak PG
Shaywitz BA. See Klorman R
Shaywitz BA, Shaywitz SE, Pugh KR, Mencl E, Fulbright RK, Skudlarski P, Constable RT, Marchione KE, Fletcher JM, Lyon GR, Gore JC. Disruption of posterior brain systems for reading in children with developmental dyslexia, 101
Shaywitz SE. See Klorman R; Shaywitz BA
Sheitman B. See Bilder RM
Shen J, Rothman DL. Magnetic resonance spectroscopic approaches to studying neuronal: glial interactions, 694
Sherr JD, Myers C, Avila MT, Elliott A, Blaxton TA, Thaker GK. The effects of nicotine on specific eye tracking measures in schizophrenia, 721
Shifflett H. See De Bellis MD
Sieghart W. See Bailer U
Siever LJ. See Mitropoulou V
Silvennoinen-Kassinen S. See Timonen M
Silverman JM. See Mitropoulou V
Skovira K. See Frank GK
Skudlarski P. See Shaywitz BA
Slate-Cothren S. See Geraci M
Smith DJ. See Yücel M
Smith M. See Geller W
Smith WA. See Wells KB
Solin O. See Laakso A
Sommers D. See Hollon SD
Spiegel D. See Krishan KRR
Stahl SM, Entsuah AR, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression, 1166
Stanley JA. See Yao JK
Stary JM. See Fatemi SH
Stein MB. See Fennema-Notestine C
Stein MB, Kennedy CM, Twamley EW. Neuropsychological function in female victims of intimate partner violence with and without posttraumatic stress disorder, 1079
Steingard RJ, Renshaw PF, Hennen J, Lenox M, Cintron CB, Young AD, Connor DF, Au TH, Yurgelun-Todd DA. Smaller frontal lobe white matter volumes in depressed adolescents, 413
Stewart J. See Flores C
Stockmeier CA. See Klimek V; Miguel-Hidalgo JJ
Stowe ZN. See Suri R
Strakowski SM. See López-Larson MP
Strangman G, Boas DA, Sutton JP. Non-invasive neuroimaging using near-infrared light, 679
Strobl R. See Bailer U
Strong MJ. See Janicak PG
Stroud LR, Salovey P, Epel ES. Sex differences in stress responses: social rejection versus achievement stress, 318
Stuart G. See Frank E
Stuart GW. See Yücel M
Stuebing KK. See Klorman R
Su J. See Wilcox MA
Suppes T. See McElroy SL; Tamminga CA
Suri R, Stowe ZN, Hendrick V, Hostetter A, Widawski M, Altshuler LL. Estimates of nursing infant daily dose of fluoxetine through breast milk, 446
Sutton JP. See Strangman G
Sutton VK. See Breier A
Syvälahti E. See Laakso A

Takahashi JS. See Merikangas KR
Takasugi K. See Matsushita S
Tamminga CA, Nemeroff CB, Blakely RD, Brady L, Carter CS, Davis KL, Dingledine R, Gorman JM, Grigoriadis DE, Henderson DC, Innis RB, Killen J, Laughren TP, McDonald WM, Murphy GM Jr, Paul SM, Rudorfer MV, Sausville E, Schatzberg AF, Scolnick EM, Suppes T. Developing novel treatments for mood disorders: accelerating discovery, 589
Taylor JR. See Jentsch JD
Teale PD. See Rojas DC
Ter Horst GJ. See Boshuisen ML
Termine A. See George TP
Thaker GK. See Sherr JD
Thakore JH. See Walsh M-T
Thatcher JE. See Klorman R
Thomas SB. See Frank E
Tillfors M, Furmark T, Marteinsdottir I, Fredrikson M. Cerebral blood flow during anticipation of public speaking in social phobia: a PET study, 1113
Timonen M, Jokelainen J, Silvennoinen-Kassinen S, Herva A, Zitting P, Xu B, Peltola O, Räsänen P. Association between skin test diagnosed atopy and professionally diagnosed depression: a Northern Finland 1966 birth cohort study, 349
Todd J. See Michie PT
Tollefson GD. See Frank E
Torrey EF. Early physical and sexual abuse associated with an adverse course of bipolar illness, 843–corr
Toschi N. See Czéh B
Trakalo JM. See Ni X
Tsuang MT. See Wilcox MA
Twamley EW. See Stein MB

Uchitomi Y, Kugaya A, Akechi T, Nakano T, Inagaki M, Matsuoka Y, Kagaya A, Yamawaki S. Lack of association between suicidal ideation and enhanced platelet 5-HT2A receptor-mediated calcium mobilization in cancer patients with depression, 1159
Unützer J. See Wells KB

van den Brink W. See Rinne T
Van Eerdewegh P. See Wilcox MA
van Honk J, Schutter DJLG, d'Alfonso AAL, Kessels RPC, de Haan EHF. 1 Hz rTMS over the right prefrontal cortex reduces vigilant attention to

unmasked but not to masked fearful faces, 312
Velakoulis D. See Yücel M
Verbaten MN. See Oranje B
Vessicchio JC. See George TP
Viana M. See Janicak PG
Videbech P. Comment on "Regional cerebral glucose utilization in patients with a range of severities of unipolar depression," 1031–corr
Vilkman H. See Laakso A
Villarreal G, Hamilton DA, Petropoulos H, Driscoll I, Rowland LM, Griego JA, Kodituwakku PW, Hart BL, Escalona R, Brooks WM. Reduced hippocampal volume and total white matter volume in posttraumatic stress disorder, 119
Vitiello B. See Frank E
Volavka J. See Bilder RM; Hoptman MJ
Vollenweider FX. See Leumann L
Vonthein R. See Köhnke MD

Wainscott C. See Alexopoulos GS; Krishan KRR
Walsh M-T, Ryan M, Hillmann A, Condren R, Kenny D, Dinan T, Thakore JH. Elevated expression of integrin aIIbbIIIa in drug-naïve, first-episode schizophrenic patients, 874
Wang K. See Rangaswamy M
Wang S. See Morgan CA III
Wei J. See Miguel-Hidalgo JJ
Weiss E. See Hoptman MJ
Weissman MM. See Costello EJ
Wells KB, Miranda J, Bauer MS, Bruce ML, Durham M, Escobar J, Ford D, Gonzalez J, Hoagwood K, Horwitz SM, Lawson W, Lewis L, McGuire T, Pincus H, Scheffler R, Smith WA, Unützer J. Overcoming barriers to reducing the burden of affective disorders, 655
Welt T. See Czéh B
Whyte EM, Mulsant BH. Post stroke depression: epidemiology, pathophysiology, and biological treatment, 253
Widawski M. See Suri R
Wienbruch C. See Fernádez A
Wilcox MA, Faraone SV, Su J, Van Eerdewegh P, Tsuang MT. Genome scan of three quantitative traits in schizophrenia pedigrees, 847
Williams LM. See Loughland CM
Williamson PC. See Lanius RA
Willinger U. See Bailer U
Willis MW. See Kimbrell TA
Winsky L. See Nestler EJ
Winter H. See Geller W
Wong C. See Yehuda R
Wong E. See Salzman C
Wood SJ. See Yücel M
Wouters L. See Rinne T
Wright BC. See Salzman C
Wright P. See Breier A

Xu B. See Timonen M

Yamada M. See Ono K
Yamawaki S. See Uchitomi Y
Yao JK, Stanley JA, Reddy RD, Keshavan MS, Pettegrew JW. Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites, 823
Yehuda R, Halligan SL, Grossman R, Golier JA, Wong C. The cortisol and glucocorticoid receptor response to low dose dexamethasone administration in aging combat veterans and Holocaust survivors with and without posttraumatic stress disorder, 393
Yeragani VK, Pesce V, Jayaraman A, Roose S. Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures, 418
Young AD. See Steingard RJ
Yücel M, Stuart GW, Maruff P, Wood SJ, Savage GR, Smith DJ, Crowe SF, Copolov DL, Velakoulis D, Pantelis C. Paracingulate morphologic differences in males with established schizophrenia: a magnetic resonance imaging morphometric study, 15
Yurgelun-Todd DA. See Steingard RJ

Zabetian CP. See Köhnke MD
Zalcman S. See Nestler EJ
Zarate CA Jr. See Payne JL
Zhang Y. See Flores C
Zhang ZJ. See Beasley CL
Ziegler S. See Hermann C
Zimmerman ME. See López-Larson MP
Zitting P. See Timonen M

Subject Index to Volume 52

Abuse
  bipolar disorder and, 843–corr
  childhood
    borderline personality disorder secondary to, 1102
    posttraumatic stress disorder secondary to, 1066
  maternal, 1047
  sexual, 843–corr
Achievement-oriented stress, 318
Adolescents
  depression in, frontal lobe gray and white matter volume reductions associated with, 413
Affective disorders
  burden of, 655
  polysomnographic studies, 430
  sleep studies, 430
  visual scanpath findings, 338
Aggression
  monoamine oxidase inhibition during brain development as inducer of, 811
  schizophrenia
    white matter microstructure alterations and, 9
Alcoholism
  electroencephalogram beta power in, 831
  excitation–inhibition imbalance in, 831
  glial density and size reductions associated with, 1121
  late-life depression and, 236
  noradrenergic function differences, 1151
  norepinephrine mediation, 1151
  plasma dopamine β-hydroxylase activity in, 1151
Alzheimer's disease
  β-amyloid fibrils
    nicotine effects on, 880
  cognitive impairment in, 907
  depression in, 242
  focal temporoparietal slow activity revealed by magnetoencephalography, 764
  presenilin-1 mutation in, 907
Amygdala. *See also* Brain
  dopaminergic abnormalities
    in major depression, 740
  glia
    in major depression, 404
  panic disorder-related differences in regional cerebral blood flow, 126
  protein kinase A stimulation in
    effects on reward-related learning in rats, 111
β-Amyloid fibrils
  nicotine effects on, in Alzheimer's disease, 880
Animal studies
  craniofacial dysmorphogenesis in schizophrenia, 716
  depression research, 502
  monoamine oxidase inhibition during brain development induces pathological aggression in mice, 811
  parental care deprivation effects on infant, 1037
  psychiatric disturbances during pregnancy and postpartum period, 1047
  startle reactivity and anxiety disorders, 958
  thalamic volume and shape abnormalities in rhesus monkeys detected with high dimensional brain mapping, 911–corr
Anorexia nervosa
  serotonin 2A receptor binding reduction after recovery from, 896
Anoxia
  dopaminergic regions affected by, 362
  ventral tegmental area basic fibroblast growth factor immunoreactivity effects, 362
Anticipatory anxiety
  in panic disorder
    regional cerebral blood flow findings associated with, 126
  in social phobia
    regional cerebral blood flow findings associated with, 1113
Antidepressants
  development of, 154–comm
  discovery of, 154–comm
  FDA summary reports of, 62
  selective serotonin reuptake inhibitors, 1166
  sleep deprivation effects, 921
Antipsychotics
  FDA summary reports of, 62
  latent inhibition effects, 729
  prepulse inhibition effects, 729, 863
  sensory gating effects, 887
Anxiety
  depression and
    description of, 73
    late-life, 236
  panic disorder-related, regional cerebral blood flow findings associated with, 126
  repetitive transcranial magnetic stimulation over prefrontal cortex effects, 312
  treatment of
    cognitive-behavioral therapy, 917–ed
    molecular targets in, 1008
Anxiety disorders
  behavioral extinction, relapse after, 976
  prevention of, 945
  risk modification for, 945
Anxiety sensitivity, 938
Ascorbic acid

© 2002 Society of Biological Psychiatry

0006-3223/02/$22.00
PII S0006-3223(02)01890-5

mood improvements using, 371
sexual intercourse frequency and, 371
Atopic diseases
depression risks and, 349
Attention-deficit/hyperactivity disorder
event probability and sequence effects, 795
frontal lobe gray and white matter volumes in, 785
math disorder, 795
reading disorder, 795
Auditory cortex
tonotopy alterations of, in schizophrenia, 32
Autism
glutamic acid decarboxylase 65 and 67 kDA protein reductions in, 805
serotonin and cerebral pathology in, 143–corr
Aversive conditioning
social phobia and, 328

Basal ganglia
blood flow
neuroleptic medications effect on, 855
caudate of, 68
idiopathic focal dystonia, 356
velo-cardio-facial syndrome and, 68
Basic fibroblast growth factors
anoxia effects on immunoreactivity of, 362
Behavioral extinction, relapse after, 976
Bipolar disorder
abuse and, 843–corr
development of, 529
dopamine D1 receptor gene and, 1144
gray matter abnormalities in, 93
natural history of, 529
physical abuse and, 843–corr
research of, 503
sexual abuse and, 843–corr
susceptibility loci for, 40
treatment of
novel types of, 589
psychosocial interventions, 610
white matter abnormalities in, 93
Borderline personality disorder
childhood abuse and, 1102
hypothalamic-pituitary-adrenal axis hyperresponsive in, 1102
Brain. *See also* Amygdala; Cerebellum; Cerebrum; Prefrontal cortex
child maltreatment-related posttraumatic stress disorder effects, 1066
diffuse optical imaging, 679–rev
monoamine oxidase inhibition development of pathological aggression secondary to, 811
morphometric studies of
in female victims of intimate partner violence with and without posttraumatic stress disorder, 1089
motor cortical excitability
in schizophrenia, 24
ventral frontal cortex morphology
in schizophrenia-related social dysfunction, 1
white matter. *See* White matter
Breast milk
fluoxetine levels in, 446
Brief dynamic therapy
late-life depression treated using, 293
Bupropion
smoking cessation in schizophrenics, 53

C-1073
psychotic major depression treated using, 386
Calbindin, 708
Calcium
serotonin 2A receptor-mediated mobilization of
in cancer patients with depression, 1159
Calcium-binding proteins
GABAergic neuron deficits in schizophrenia detected by, 708
Calretinin, 708
Catecholamines
parental care deprivation effects on, 1037
Catechol-*O*-methyltransferase Val_{158}Met polymorphism, 701
Cerebellum. *See also* Brain
glutamic acid decarboxylase 65 and 67 kDA protein reductions
in autism patients, 805
Cerebrospinal fluid
5-HIAA levels
suicide attempts and, 375–corr
Cerebrovascular accident. *See* Stroke
Cerebrum. *See also* Brain
autism and, 143–corr
glucose utilization, in unipolar depression, 1031–corr
regional blood flow
panic disorder-related differences in, 126
social phobia effects on, 1113
Children
attention-deficit/hyperactivity disorder in, 785, 795
dyslexia, neural system disruptions in, 101
hypothalamic-pituitary-adrenal activity, 776
major depression in
dorsolateral prefrontal cortex abnormalities associated with, 86
maltreated, posttraumatic stress disorder secondary to, 1066
math disorder, 795
posttraumatic stress disorder in, 1066
reading disorder, 795
stress in
description of, 773–ed
maternal stress effects on sensitization to, 776
Chromosome 6, 847
Chromosome 3q
susceptibility loci on, for schizophrenia and bipolar disorder, 40
Cingulate cortex
morphologic differences in schizophrenic men, 15
Clinical trials
CONSORT standards, 62

mood disorders, 631
Cognitive impairment
in Alzheimer's disease, 907
in schizotypal personality disorder, 1175
Cognitive-behavioral therapy
anxiety treated using, 917–ed, 938
late-life depression treated using, 293
pharmacotherapy and, 917–ed, 986
Conditioning
aversive, social phobia and, 328
fear, 927, 958
CONSORT standards, 62
Corpus callosum
genu decreases in dysthymia and depressive personality disorder, 1134
Cortisol
depression and, 381–comm
dexamethasone effects on
in posttraumatic stress disorder patients, 393
parental care deprivation effects on, 1037
stress-induced release of, 136, 776
Craniofacial dysmorphogenesis, 716
Cued fear learning, 958

Depression. *See also* Major depression
adolescent
frontal lobe white matter volumes in, 413
Alzheimer's disease, 242
anxiety and, 73
atopic diseases and, 349
brain electrical tomography in, 73
in cancer patients
lack of association between suicidal ideation and serotonin 2A receptor-mediated calcium mobilization, 1159
corpus callosum genu decreases associated with, 1134
cortisol's role in, 381–comm
development of, 529
diagnosis of, 145–ed
early-onset, 1134
frontal lobe involvement in, 73
glucocorticoid receptor in, 381–comm
melancholic features of, 73
natural history of, 529
post stroke, 253
research of, 503
treatment of
novel types of, 589
psychosocial interventions, 610
selective serotonin reuptake inhibitors, 1166
unmet needs in, 145
venlafaxine, 1166
unipolar
regional cerebral glucose utilization in, 1031–corr
Dexamethasone
corticotropin-releasing hormone challenge, 1102
cortisol and glucocorticoid receptor effects
in posttraumatic stress disorder patients, 393
Diffuse optical brain imaging, 679–rev
Dissociation
posttraumatic stress disorder
prefrontal and limbic structures' role in, 305
Domestic violence. *See* Intimate partner violence
Dopamimetic-induced psychosis
olanzapine for
in Parkinson's disease, 438
Dopamine
amygdala abnormalities of
in major depression, 740
β-hydroxylase activity
in alcoholism, 1151
prepulse inhibition and, 887
Dopamine D1 receptor gene
bipolar disorder and, 1144
Dopaminergic regions
anoxia effects on, 362
Drug addiction
alcohol. *See* Alcoholism
protein kinase A stimulation in amygdala effects, 111
Dyslexia
neural system disruptions in, 101
Dysthymia
corpus callosum genu decreases associated with, 1134

Elderly
depression in
alcohol use disorders and, 236
anxiety and, 236
assessment of, 164
biological risk factors, 185
cancer and, 559
cognitive-behavioral therapy for, 293
combined psychotherapy/pharmacotherapy for, 293
comorbidities, 236, 543, 559
diagnosis of, 157
drug treatment of, 265
electroconvulsive treatment of, 265
heart disease and, 559
medical comorbidity, 226, 559
non-suicide mortality risks secondary to, 205
Parkinson's disease, 559
personality disorders and, 236
primary care treatment of, 285
psychosocial risk factors, 175
psychotherapy for, 293
research of, 543
stroke and, 559
treatment of, 265, 285, 543
mood disorders in
patient perspective of, 148–comm
suicide risks associated with, 193
Electroconvulsive therapy
late-life depression treated using, 265
transcranial magnetic stimulation vs.
for major depression, 1032–corr
Electroencephalogram

alcoholism evaluations using, 831
Emotions
prefrontal cortex, 312
research of, 773–ed
Epinephrine
parental care deprivation effects on, 1037
Errata
Hirshfeld-Becker article (2001;50:563-574), 379
Rasmusson article (2001;50:965-977), 771
Siegle article (2001;51:693-707), 771
Extinction
behavioral
relapse after, 976
fear, 998

Fear(s)
cognitive-behavioral therapy for, 917–ed
conditioning of, 927, 958
extinction
glutamate and gamma-aminobutyric acid in, 998
"unlearning" of, 917–ed
Fear learning, 958, 998
Fear module, 927
Fluoxetine
breast milk concentrations of, 446
Focal dystonia, idiopathic
obsessive compulsive disorder and, 356
Food and Drug Administration
summary reports of antidepressants and antipsychotics, 62
Frontal lobe gray and white matter volume
in adolescent depression, 413
in attention-deficit/hyperactivity disorder, 785

GABAergic neuron deficits
in schizophrenia
calcium-binding proteins for detecting the presence of, 708
Gamma-aminobutyric acid
fear extinction and, 998
Gender. *See also* Men; Women
stress response differences, 318
strial presynaptic dopamine synthesis differences, 759
Genetics
mood disorders research, 457
schizophrenia
chromosome 6 linkage, 847
description of, 749
genome scan, 847
susceptibility loci
for bipolar disorder, 40
for schizophrenia, 40
Genome scan
quantitative traits in schizophrenia pedigrees, 847
susceptibility loci for schizophrenia and bipolar disorder evaluated using, 40
Glia
alcohol dependence-related decreases in density and size of, 1121
amygdala
in major depression, 404
lithium effects, 404
neuronal interactions with
magnetic resonance spectroscopy approaches for studying, 694
valproate effects, 404
Glucocorticoid receptor
antagonists
major depression treated using, 386
depression and, 381–comm
dexamethasone effects on
in posttraumatic stress disorder patients, 393
Glucose
regional cerebral utilization of
in unipolar depression, 1031–corr
Glutamate
fear extinction and, 998
glutamine cycling with, 694
Glutamic acid decarboxylase, 805
Gray matter
adolescent depression-related volume decreases in, 413
attention-deficit/hyperactivity disorder-related volumes, 785
bipolar disorder-related abnormalities, 93

Haloperidol
sensory gating effects of, 887
Heart rate
nortriptyline effects, 418
paroxetine effects, 418
5-HIAA
cerebrospinal fluid levels of
and suicide attempts, 375–corr
Hippocampus
posttraumatic stress disorder-related volume reductions in, 119, 1089
stress-induced structural remodeling in, 1057
5-HT2A receptor
anorexia nervosa-related reductions in binding of, 896
platelet responses in
and suicidal ideation in cancer patients with depression, 1159
Hypothalamic-pituitary-adrenal system
description of, 1057
hyperresponsive of
in borderline personality disorder, 1102

Idiopathic focal dystonia
obsessive compulsive disorder and, 356
Impulsivity in schizophrenia
white matter microstructure alterations and, 9
Infant
fluoxetine intake through breast milk, 446
parental care deprivation effects on
primate studies of, 1037
psychiatric disturbances during pregnancy and postpartum period effect, 1047
Integrin $\alpha_{IIb}\beta_{IIIa}$
schizophrenia expression of, 874
Intimate partner violence in women

brain morphometry studies, 1089
neuropsychological function effects, 1079
Ischemic heart disease
major depression and, 418

Ketamine
sensory gating effects of, 887

Late-life depression
alcohol use disorders and, 236
anxiety and, 236
assessment of, 164
biological risk factors, 185
cancer and, 559
cognitive-behavioral therapy for, 293
combined psychotherapy/pharmacotherapy for, 293
comorbidities, 236, 543, 559
diagnosis of, 157
drug treatment of, 265
electroconvulsive treatment of, 265
heart disease and, 559
medical comorbidity and, 226, 559
non-suicide mortality risks secondary to, 205
Parkinson's disease, 559
personality disorders and, 236
primary care treatment of, 285
psychosocial risk factors, 175
psychotherapy for, 293
research of, 543
stroke and, 559
treatment of, 265, 285, 543
Latent inhibition, 729
Lithium
amygdala glia affected by, 404
Locus coeruleus
noradrenergic projection quiescence during REM sleep, 921
Lovastatin
quetiapine coadministration with
QTc interval prolongation associated with, 914–corr

Magnetic resonance imaging
cingulate morphologic differences in schizophrenic men evaluated using, 15
functional, 679–rev
Magnetic resonance spectroscopy
neuronal–glial interactions studied using, 694
Magnetic stimulation, transcranial
electroconvulsive therapy vs.
for major depression, 1032–corr
motor cortical excitability in schizophrenia evaluated using, 24
repetitive
fear-related studies using, 312
psychosocial stress evaluated using, 1057
selective attention effects, 312
Magnetoencephalography
Alzheimer's disease-related focal temporoparietal slow activity revealed by, 764
Major depression. *See also* Depression
amygdala glia in, 404
dopaminergic abnormalities in amygdala in, 740
dorsolateral prefrontal cortex abnormalities in, 86
electroconvulsive therapy for, 1032–corr
ischemic heart disease and, 418
pediatric
proton magnetic resonance spectroscopic imaging in, 86
psychotic, C-1073 for, 386
sleep disturbances associated with, 430
transcranial magnetic stimulation for, 1032–corr
Maternal abuse, 1047
Maternal stress
animal studies of, 1047
childhood sensitization to stress caused by, 776
Men. *See also* Gender; Sex differences
schizophrenia
aggression, 9
cingulate cortex morphologic differences in, 15
impulsivity, 9
white matter microstructure in, 9
stress responses of, 318
Mifepristone
psychotic major depression treated using, 386
Mismatch negativity, 749
Monoamine oxidase inhibition
during brain development
pathological aggression secondary to, 811
Mood
ascorbic acid effects on, 371
behavioral substrates of, 478
neural substrates of, 478
Mood disorders
bipolar disorder. *See* Bipolar disorder
clinical trials for, 631
depression. *See* Depression
development of, 529
diagnosis of, 145
in elderly
patient perspective of, 148–comm
suicide risks associated with, 193
major depression. *See* Major depression
natural history of, 529
novel treatments for, 589
psychosocial interventions for, 610
research
genetics of, 457
NIMH strategic plan for, 455–ed
plan for, 631
translation, 631
treatment of, 145
Motor cortical excitability
in schizophrenia, 24
MRI. *See* Magnetic resonance imaging
MRS. *See* Magnetic resonance spectroscopy

National Institutes of Mental Health
mood disorders research strategies, 455–ed

Near-infrared light, 679–rev
Neural system disruption
in dyslexia, 101
Neuroimaging
near-infrared light for, 679–rev
Neuroleptic medications
basal ganglia blood flow effects of, 855
Neuroleptics
motor cortical excitability associated with, 24
Neuronal–glial interactions
magnetic resonance spectroscopy for studying, 694
Neuropeptide-Y
stress-induced release of, 136
Nicotine
antiamyloidogenic effect of, 880
smooth pursuit eye movement effects
in schizophrenia patients, 721
Norepinephrine
alcoholism mediation by, 1151
parental care deprivation effects on, 1037
Nortriptyline
heart rate variability effects, 418
Nursing infant
fluoxetine intake through breast milk, 446

Obsessive compulsive disorder
idiopathic focal dystonia and, 356
Olanzapine
dopamimetic-induced psychosis in Parkinson's disease patients treated using, 438

P50 suppression, 887
Panic attacks during sleep
pentagastrin-induced, 1183
Panic disorder
anticipatory anxiety in
regional cerebral blood flow findings associated with, 126
anxiety sensitivity in, 938
Parental care deprivation
primate studies of, 1037
Parietal lobe
glutamic acid decarboxylase 65 and 67 kDA protein reductions
in autism patients, 805
Parkinson's disease
depression and, 558
dopamimetic-induced psychosis treated using olanzapine, 438
Paroxetine
heart rate variability effects, 418
Parvalbumin, 708
Pentagastrin-induced sleep panic attacks, 1183
Personality disorders
borderline
childhood abuse and, 1102
hypothalamic-pituitary-adrenal axis hyperresponsive in, 1102
late-life depression and, 236
schizotypal
cognitive impairment in, 1175
neuropsychological performance testing in, 1175
Pharmacotherapy and cognitive-behavioral therapy, for anxiety disorders
description of, 917–ed
efficacy of, 987
Phobias
fear conditioning, 927
fear module for, 927
social. *See* Social phobia
Phospholipid metabolites
polyunsaturated fatty acids and
in schizophrenia, 823
Plasticity gene upregulation
sleep deprivation-related antidepressant effects secondary to, 921
Platelet surface receptors
in schizophrenia, 874
Polysomnography
affective disorder studies using, 430
Polyunsaturated fatty acids
phospholipid metabolites and
in schizophrenia, 823
Positron emission tomography
regional cerebral blood flow during anticipation of public speaking in social phobia evaluated using, 1113
Postpartum psychiatric disturbances, 1047
Posttraumatic stress disorder
child maltreatment-related, 1066
dexamethasone effects on cortisol and glucocorticoid receptor in, 393
dissociative responses in, 305
hippocampal volume reductions in, 119, 1089
intimate partner violence in women and
brain morphometry studies, 1089
neuropsychological function, 1066
script-driven imagery studies in, 305
white matter volume reductions in, 119
Prefrontal cortex. *See also* Brain
depression-related pathology, 73, 86
dorsolateral, 86, 1121
emotions in, 312
glial density and size reductions
in alcoholism, 1121
gray matter abnormalities
in bipolar disorder, 93
repetitive transcranial magnetic stimulation over, 312
Pregnancy
psychiatric disturbances during, 1047
Prepulse inhibition
antipsychotics effect on, 729, 863
dopaminergic activity and, 887
startle response, 863
Presenilin-1 mutation
in Alzheimer's disease, 907
Primary care
late-life depression treated using, 285

Protein kinase A
amygdala, effects on reward-related learning in rats, 111
Proton magnetic resonance spectroscopic imaging
pediatric major depression evaluated by, 86
Psychosis
dopamimetic-induced
olanzapine for, 438
Psychotherapy
late-life depression treated using, 293
PTSD. *See* Posttraumatic stress disorder

QTc interval prolongation
quetiapine and lovastatin coadministration as possible cause of, 914–corr
Quetiapine
lovastatin coadministration with, QTc interval prolongation associated with, 914–corr

Radiation
thalamic volume and shape abnormalities in rhesus monkeys with fetal exposure to, 911–corr
Regional cerebral blood flow
anticipatory anxiety findings, 126
panic disorder patients during anticipatory anxiety, 126
REM sleep
locus coeruleus noradrenergic projection quiescence during, 921
Repetitive transcranial magnetic stimulation
psychosocial stress evaluated using, 1057
right prefrontal cortex
effects on anxiety, 312
selective attention effects, 312
Research
bipolar disorder, 503
depression
preclinical models, 503
emotion, 773–ed
mood disorders
genetics of, 457
NIMH strategic plan for, 455–ed
plan for, 631
translation, 631
Risk factors
atopic disease and depression, 349
late-life depression, 185

Schizophrenia
aggression in
white matter microstructure alterations and, 9
atypical antipsychotics for, 729
auditory cortex tonotopy alterations in, 32
auditory perception deficits in, 32
basal ganglia blood flow in
neuroleptic medications effect on, 855
cardiovascular illness risks, 874
catechol-*O*-methyltransferase Val_{158}Met polymorphism in, 701
cingulate morphology in, 15
craniofacial dysmorphogenesis in, 716
familial factors, 749
GABAergic neuron deficits in
calcium-binding proteins for detecting the presence of, 708
genetics of
chromosome 6 linkage, 847
description of, 749
genome scan, 847
impulsivity in, white matter microstructure alterations and, 9
integrin $\alpha_{IIb}\beta_{IIIa}$ expression in, 874
latent inhibition in, 729
membrane abnormalities in, 823
mismatch negativity in, 749
neurocognitive deficits, 701
neurodevelopmental hypothesis of, 716
neuronal nicotinic receptors in, 721
nicotine effects on specific eye tracking measures in, 721
platelet surface receptors in, 874
polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites, correlations between, 823
prepulse inhibition in, 729, 863
smoking cessation in, using bupropion, 53
social dysfunction in, 1
startle response in, 863
susceptibility loci for, 40
thalamic neuropathology findings, 716
ventral frontal cortex morphology in, 1
visual scanpath findings, 338
Schizotypal personality disorder
cognitive impairment in, 1175
neuropsychological performance testing in, 1175
Script-driven imagery
posttraumatic stress disorder-related dissociation studies using, 305
Selective serotonin reuptake inhibitors
venlafaxine vs.
for depression, 1166
Sensory gating
haloperidol effects on, 887
ketamine effects on, 887
Serotonin
cerebral pathology in autism and, 143–corr
Serotonin 2A receptor
anorexia nervosa-related reductions in binding of, 896
platelet responses in
and suicidal ideation in cancer patients with depression, 1159
Sex differences. *See also* Men; Women
stress responses, 318
strial presynaptic dopamine synthesis, 759
Sexual abuse
bipolar disorder and, 843–corr
Sexual intercourse
ascorbic acid effects on frequency of, 371
Sleep
major depression-related disturbances, 430

panic attacks during, induced by pentagastrin, 1183
polysomnography studies, 430
Sleep deprivation
antidepressant effects of, 921
Smoking
cessation using bupropion, 53
nicotine
antiamyloidogenic effect of, 880
smooth pursuit eye movement effects, in schizophrenia patients, 721
schizophrenia and, 53
Smooth pursuit eye movements
nicotine effects on, in schizophrenia patients, 721
Social dysfunction
in schizophrenia, 1
Social phobia
anticipatory anxiety effects, 1113
aversive conditioning in, 328
public speaking anticipation effects on regional cerebral blood flow in patients with, 1113
Social rejection stress, 318
Startle response
anxiety disorders and, 958
prepulse inhibition and, 863
schizophrenia, 863
Stress. *See also* Posttraumatic stress disorder
achievement-oriented, 318
children, 773–ed
cortisol levels, 136, 776
hippocampus-related structural remodeling secondary to, 1057
hormone levels
repetitive transcranial magnetic stimulation effects on, 1057
maternal
animal studies of, 1047
effect on childhood sensitization to stress, 776
neuropeptide-Y levels, 136
pregnancy-related, 1047
sex differences in responses to, 318
social rejection, 318
Strial dopaminergic function, 759
Stroke
depression after, 253, 559
Suicide
cerebrospinal fluid 5-HIAA levels in, 375–corr
elderly with mood disorders, 193
serotonin 2A receptor-mediated calcium mobilization and in cancer patients with depression, 1159
Susceptibility loci
for bipolar disorder, 40
for schizophrenia, 40
Temporoparietal areas
slow activity of
in Alzheimer's disease, 764
Thalamus
volume and shape abnormalities in rhesus monkeys
detected with high dimensional brain mapping, 911–corr
Thioflavin T, 880
Transcranial magnetic stimulation
electroconvulsive therapy vs.
for major depression, 1032–corr
motor cortical excitability in schizophrenia evaluated using, 24
repetitive
fear-related studies using, 312
psychosocial stress evaluated using, 1057
selective attention effects, 312

Unlearning
extinction vs., 976
fears, 917–ed

Valproate
amygdala glia affected by, 404
Velo-cardio-facial syndrome
basal ganglia volumes in, 68
Venlafaxine
selective serotonin reuptake inhibitors vs.
for depression, 1166
Visual scanpaths
affective disorders, 338
schizophrenia, 338

White matter
adolescent depression-related volume decreases in, 413
attention-deficit/hyperactivity disorder-related volumes, 785
bipolar disorder-related abnormalities, 93
microstructure of
impulsivity and aggression in schizophrenic men, 9
posttraumatic stress disorder-related volume reductions in, 119
Women. *See also* Gender; Sex differences
borderline personality disorder in
hypothalamic-pituitary-adrenal system
hyperresponsiveness to combined dexamethasone/corticotropin-releasing hormone challenge in, 1102
intimate partner violence
brain morphometry studies, 1089
neuropsychological function effects, 1079
stress responses of, 318